SCHEMBL1775668

SCHEMBL1775668

CO[C@H]1O[C@H](COS(=O)(=O)c2ccc(C)cc2)[C@@H](OC(=O)c2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.47
SSTR1 P30872 1/20 0.44
SSTR2 P30874 1/20 0.44
SSTR4 P31391 1/20 0.44
SSTR3 P32745 1/20 0.44
SSTR5 P35346 1/20 0.44
LGALS3 P17931 4/20 0.44
LGALS4 P56470 3/20 0.44
PTPN1 P18031 5/20 0.44
PTPN2 P17706 2/20 0.44
BCHE P06276 1/20 0.41
FGF1 P05230 2/20 0.40
FGF2 P09038 2/20 0.40
VEGFA P15692 2/20 0.40
HPSE Q9Y251 2/20 0.40
MAPT P10636 1/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
LGALS9 O00182 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1777133 0.92 NT5E (0.43) NT5ESSTR1SSTR2SSTR4SSTR3
SCHEMBL5680059 0.90 LGALS3 (0.49) LGALS3LGALS4PTPN1PTPN2CA1
SCHEMBL4306018 0.86 LGALS3 (0.47) LGALS3LGALS4PTPN1FGF1FGF2
SCHEMBL1778308 0.85 LGALS3 (0.44) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1777369 0.84 MAPT (0.39) NT5ELGALS3LGALS4FGF1FGF2
SCHEMBL1777367 0.84 MAPT (0.39) NT5ELGALS3LGALS4FGF1FGF2
SCHEMBL18279685 0.84 NT5E (0.52) NT5ESSTR1SSTR2SSTR4SSTR3
SCHEMBL18279684 0.84 NT5E (0.52) NT5ESSTR1SSTR2SSTR4SSTR3
SCHEMBL28316892 0.84 FGF1 (0.52) NT5ESSTR1SSTR2SSTR4SSTR3
SCHEMBL17040056 0.80 NT5E (0.62) NT5ESSTR1SSTR2SSTR4SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 US disclosed
EP-1589023-A1 OLIGOSACCHARIDE DERIVATIVE Sankyo Company, Limited (JP) 2005-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A NT5E 1662/4885SSTR1 879/4885SSTR2 1191/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 NT5E 3836/4885SSTR1 373/4885SSTR2 379/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 NT5E 3836/4885SSTR1 373/4885SSTR2 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.